Investigations of interferon-lambda for the treatment of cancer

Journal of Innate Immunity

Volumn 7, Issue 3, 2015, Pages 243-250

  Stiff, Andrew ^a   Carson Iii, William ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Cancer; Cytokines; Immune response; Interferon lambda; NK cells

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON LAMBDA; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; CYTOKINE RECEPTOR; IFNLR1 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; INTERFERON;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE SPECIFICITY; TUMOR IMMUNITY; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; NEOPLASMS; RECEPTORS, CYTOKINE;

EID: 84929023079     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000370113     Document Type: Review

References (47)

1. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA: Interferon lambda: A new sword in cancer immunotherapy. Clin Dev Immunol 2011; 2011: 349575.
2. Steen HC, Gamero AM: Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 2010; 30: 597-602.
3. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
4. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68.
5. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV: Characterization of the mouse IFN-lambda ligand-receptor system: IFNlambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66: 4468-4477.
6. Boglione L, Cusato J, Allegra S, Esposito I, Patti F, Cariti G, Di Perri G, D'Avolio A: Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res 2014; 102: 35-43.
7. Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S: Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 2013; 11: 6.
8. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R: Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009; 284: 20869-20875.
9. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR: Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509.
10. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR: An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-2485.
11. Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC: Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J 2003; 370: 391-396.
12. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC: Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269-32274.
13. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM: IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/ STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-1115.
14. Lasfar A, Cohen-Solal KA: Emergence of IFN-lambda as a potential antitumor agent; in You Y (ed): Targets in Gene Therapy. 2011, InTech, DOI: 10.5772/18783.
15. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K: Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10: 702-714.
16. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat R: Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008; 83: 1181-1193.
17. Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN) is expressed in a tissuedependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
18. Zhang L, Fok JJ, Mirabella F, Aronson LI, Fryer RA, Workman P, Morgan GJ, Davies FE: Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett 2013; 339: 49-59.
19. Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, Blaskovits FM, Young GS, Nuovo GJ, Mundy BL, Lesinski GB, Carson WE 3rd: Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther 2010; 9: 510-520.
20. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G: Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8: 254-261.
21. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G: IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009; 113: 5829-5838.
22. Ding S, Khoury-Hanold W, Iwasaki A, Robek MD: Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol 2014; 12:e1001758.
23. Pasquali S, Mocellin S: The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma. Curr Med Chem 2010; 17: 3327-3336.
24. Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, Tomasello G, Vaglio A, Labianca R, Rondini E, Sabbatini R, Nastasi G, Artioli F, Prati A, Potenzoni M, Pezzuolo D, Oliva E, Alberici F, Buzio C; POLAR-01 Trial Investigators: Adjuvant low-dose interleukin-2(IL-2) plus interferon-alpha (IFNalpha) in operable renal cell carcinoma (RCC): A phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J Immunother 2014; 37: 440-447.
25. Khoo TL, Vangsted AJ, Joshua D, Gibson J: Interferon-alpha in the treatment of multiple myeloma. Curr Drug Targets 2011; 12: 437-446.
26. Stein BL, Tiu RV: Biological rationale and clinical use of interferon in the classical BCRABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res 2013; 33: 145-153.
27. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/ S9512/C509801. J Clin Oncol 2001; 19: 2370-2380.
28. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
29. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A: Effect of longterm adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 2001; 358: 866-869.
30. Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390-402.
31. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T: Antitumor activity of IFN-lambda in murine tumor models. J Immunol 2006; 176: 7686-7694.
32. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M: IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007; 178: 5086-5098.
33. Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, Pavelko K, Pease L, Melcher A, Vile R: Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 2010; 70: 4539-4549.
34. Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV: Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 2010; 59: 1059-1071.
35. Tezuka Y, Endo S, Matsui A, Sato A, Saito K, Semba K, Takahashi M, Murakami T: Potential anti-tumor effect of IFN-2 (IL-28A) against human lung cancer cells. Lung Cancer 2012; 78: 185-192.
36. Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, Shimada H, Tagawa M: Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 2010; 46: 180-190.
37. Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, Nakayama K, Numasaki M: Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 2011; 102: 1977-1990.
38. Zitzmann K, Brand S, Baehs S, Göke B, Meinecke J, Spottl G, Meyer H, Auernhammer CJ: Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006; 344: 1334-1341.
39. Cannella F, Scagnolari C, Selvaggi C, Stentella P, Recine N, Antonelli G, Pierangeli A: Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med Microbiol Immunol 2014; 203: 177-184.
40. Tagawa M, Kawamura K, Li Q, Tada Y, Hiroshima K, Shimada H: A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects. Clin Dev Immunol 2011; 2011: 479013.
41. Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M: Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects. Br J Cancer 2011; 105: 1302-1312.
42. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV: Regulation of apoptosis by type III interferons. Cell Prolif 2008; 41: 960-979.
43. Burkart C, Arimoto K, Tang T, Cong X, Xiao N, Liu YC, Kotenko SV, Ellies LG, Zhang DE: Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN and elevated secretion of Cxcl10. EMBO Mol Med 2013; 5: 967-982.
44. Fridman WH, Pages F, Sautes-Fridman C, Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
45. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
46. Drake CG, Lipson EJ, Brahmer JR: Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11: 24-37.
47. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.